Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.7
16.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Long-Term Investments
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Long-Term Investments
¥72.8m
|
CAGR 3-Years
124%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Investments
¥684.7m
|
CAGR 3-Years
189%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Long-Term Investments
¥571.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Investments
¥1.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
53%
|
CAGR 10-Years
77%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Investments
¥12.7B
|
CAGR 3-Years
120%
|
CAGR 5-Years
31%
|
CAGR 10-Years
68%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Investments
¥1.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Glance View
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. is a holding company that engages in the research, development, manufacture and sale of biochemical pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 1,006 full-time employees. The company went IPO on 2017-07-19. The firm's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The firm mainly exports its products to the United States and European countries.
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Long-Term Investments?
Long-Term Investments
72.8m
CNY
Based on the financial report for Sep 30, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Long-Term Investments amounts to 72.8m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
70%
Over the last year, the Long-Term Investments growth was 6%. The average annual Long-Term Investments growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 124% over the past three years , 70% over the past five years .
You don't have any saved screeners yet
